ACB $1.350 (2.27%)

ACNNF $0.024 (0%)

AERO $3.210 (0%)

ALEAF $0.054 (0%)

AMMJ $0.040 (0%)

APHA $15.380 (0%)

ARNA $99.990 (0%)

ATT:CNX $0.080 (0%)

AUSA:CNX $0.090 (12.5%)

AUSAF $0.080 (5.13%)

AVXL $10.300 (2.9%)

BAMM:CNX $0.140 (3.7%)

BBM:CNX $0.035 (0%)

BBRRF $0.025 (-21.38%)

BE:CNX $0.005 (0%)

BIO:CNX $0.025 (0%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.440 (2.33%)

BLOZF $0.345 (0%)

BUDZ $0.100 (0%)

CADMF $0.052 (0%)

CALI:CNX $0.080 (0%)

CANN $0.235 (4.36%)

CARA $8.620 (-5.59%)

CBWTF $0.064 (4.27%)

CGC $2.810 (-1.4%)

CGRW $0.020 (33.33%)

CHOO:CNX $0.005 (0%)

CHOOF $0.003 (20%)

CNBX $3.540 (0%)

CNGGF $0.198 (0%)

CODI $21.550 (0.61%)

CPMD $0.017 (2.45%)

CRBP $0.258 (2.42%)

CRON $2.860 (1.42%)

CROP:CNX $0.015 (0%)

CSI:CNX $0.120 (0%)

CURR $0.295 (13.46%)

CVSI $0.037 (2.78%)

DIGP $0.012 (-4%)

EEVVF $0.078 (0%)

EMHTF $0.039 (4%)

EPWCF $0.078 (3.6%)

FFT:CNX $0.040 (0%)

FNNZF $0.067 (0%)

GNBT $0.001 (0%)

GRIN:CNX $0.090 (0%)

GRWG $3.790 (5.57%)

GTBIF $7.970 (-0.38%)

GTII:CNX $10.280 (-2.19%)

GWPH $218.960 (0%)

HEXO $0.211 (0.67%)

HHPHF $0.079 (0%)

HLSPY $0.363 (0%)

HMLSF $2.600 (-4.41%)

HMPPF $0.498 (0%)

HRVOF $0.022 (12.69%)

HSTRF $0.135 (0%)

HUGE:CNX $1.020 (-3.77%)

IAN:CNX $0.080 (0%)

IGC $0.510 (-3.77%)

IGXT $0.170 (0.36%)

IIPR $111.940 (1.88%)

INQD $0.011 (-11.67%)

IONC:CNX $0.005 (0%)

IONKF $0.003 (-1.43%)

ISOL:CNX $0.035 (0%)

ITHUF $0.064 (-1.41%)

KBEV:CNX $0.045 (0%)

KHRNF $0.101 (7.72%)

KSHB $0.695 (0%)

LHS:CNX $1.470 (0%)

LHSIF $1.145 (0%)

LXX:CNX $8.400 (0%)

MCIG $0.028 (0%)

MEDIF $0.060 (7.43%)

MGWFF $0.064 (14.9%)

MJ:CNX $0.065 (0%)

MJNA $0.013 (-0.76%)

MNTR $0.040 (0%)

MYM:CNX $0.140 (0%)

MYMMF $0.106 (0%)

NCNNF $0.058 (0%)

NDVAF $0.124 (2.26%)

NGW:CNX $0.410 (0%)

NRXCF $0.014 (0%)

NSPDF $0.008 (0%)

NVTQF $0.590 (0%)

NWKRF $0.424 (0%)

NXGWF $0.316 (0%)

NXTTF $0.040 (15.76%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

PHCG $0.020 (-4.76%)

PHVAF $0.038 (0%)

PILL:CNX $0.300 (20%)

PKG:CNX $0.020 (0%)

PLPRF $0.357 (0%)

PLUS:CNX $0.440 (0%)

PMCB $2.240 (0%)

PNPL $0.012 (0%)

PTNYF $0.018 (-2.43%)

QCA:CNX $0.100 (0%)

RDDTF $0.021 (-0.7%)

RLLVF $0.001 (0%)

RMHB $0.016 (-18.5%)

RQB:CNX $0.005 (0%)

RQHTF $0.370 (0%)

SLNG:CNX $0.120 (14.29%)

SMG $80.180 (1.51%)

SNN:CNX $0.155 (0%)

SOL:CNX $0.370 (-14.94%)

SOLCF $0.315 (4.56%)

SPLIF $0.020 (75.44%)

SPRWF $0.268 (0%)

STEM:CNX $0.035 (-12.5%)

STMH $0.024 (-3.1%)

SUN:CNX $0.150 (0%)

TBPMF $0.046 (3.87%)

TCAN:CNX $0.095 (-36.67%)

TCNAF $0.110 (0%)

TER:CNX $2.945 (-9.38%)

TGEN $1.274 (12.74%)

TGIF:CNX $0.025 (-16.67%)

TGIFF $0.023 (6.98%)

THC:CNX $0.055 (10%)

THCBF $0.041 (-3.31%)

TLRY $3.150 (0.96%)

TRLFF $0.045 (0%)

TRSSF $2.370 (3.95%)

TURV $0.001 (0%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.025 (0%)

VPRB $0.028 (0%)

VRTHF $0.018 (0%)

VVCIF $0.030 (-10.58%)

WAYL:CNX $0.740 (0%)

XXII $2.130 (0%)

ZDPY $0.715 (0%)

ZYNE $1.170 (2.63%)

Back

Khiron Life Sciences Has Made Its First Entry Point Into The Mexican Cannabis Market Ahead Of Adult Use Coming Online In The Near Future

Apr 4, 2022 • 7:53 AM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Mexico is considered to be one of the most attractive cannabis markets in Latin America and is a region that we are highly focused on. So far, we have identified several companies that are working tirelessly to execute on a strategy to provide leverage to the market prior to recreational cannabis being legalized. 

Last year, we highlighted Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) as a Latin American cannabis company with leverage to Mexico and believe our readers need to be aware of this aspect of the business. 

Forms Partnership with Leading Medical Center in Mexico

Through a partnership with Teleton, the Latin American cannabis company can provide medical cannabis to more than 24 medical centers across Mexico (centers include: 22 rehabilitation centers, an autism center, and a children’s hospital for cancer). More than half a million patients are treated at Teleton clinics and we consider the relationship to be a cornerstone of Khiron’s business in Mexico.

During the last year, Khiron has opened several Zerenia ™ medical cannabis clinics in South America (Colombia and Peru). We believe this distribution outlet provides the business with a proprietary, sustainable growth model and are bullish on the opportunity for Khiron to replicate this model in Teleton’s medical centers across Mexico. 

The partnership provides both companies with attractive leverage to Mexico’s emerging cannabis market and will monitor how this aspect of the story advances. Included in the partnership is the establishment of Khiron’s Zerenia™ medical cannabis clinics within Teleton’s network across Mexico, the distribution of Khiron’s medical cannabis products in Teleton’s pharmacies, and the training of Teleton employees on the delivery of medical cannabis.

We believe the combination of Teleton’s network with Khiron’s approach to treating patients with medical cannabis is a recipe for success and will monitor how the teams can execute. Khiron combines a patient-oriented approach with physician education programs, scientific expertise, and product innovation, are we are favorable with the track record that is associated with the approach. 

Khiron Could be a Latin American Cannabis Leader

Earlier this week, Khiron reported a major milestone and obtained regulatory quotas from Mexico’s regulatory agency for importing cannabidiol (CBD) and tetrahydrocannabinol (THC). Now, the company is securing import permits to start making commercial sales and expect this to be a major growth catalyst for the business. 

Another important aspect of the Khiron story is its partnership with Mexico’s top university Tecnologico de Monterrey. Through the relationship, the company will provide medical cannabis training to doctors across the country that is based on its education programs and real-world evidence from its Zerenia™ clinics across Latin America.

Mexico is considered one of the most attractive cannabis markets due to the size of it. With a population of approx. 130 million people, Khiron will be able to treat up to millions of patients with medical cannabis. The company is considered to be a potential medical cannabis leader with its specialized end-to-end solution and we will monitor how its fundamentals improve once it starts generating revenue in Mexico. 

If you are interested in learning more about Khiron Life Sciences’ leverage to Mexico, please send an email to support@technical420.com with the subject “Khiron Life Sciences in Mexico” to be added to our distribution list. 

For the fastest access to data on Khiron Life Sciences, sign up for our free newsletter!

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners LLC. SBP continues to drive market awareness for leading firms in the cannabis industry throughout the U.S. and abroad.

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Technical420 newsletter.

 All good -- no spamming here.